Type 1 diabetes patients who are 18 – 40 years
Evaluate the Safety of TOL-3021 in Patients With New Onset or Established diagnosis of Type 1 diabetes within 5 years of screening.
Study Length: 52 Weeks
Target Age/Sex: 18 – 40 years, Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures